McAllen Optometrist Fred Farias III Elected to American Optometric Association’s Board of Trustees

Translate to Spanish or other 102 languages!

Fred Farias III, O.D., F.A.A.O
Fred Farias III, O.D., F.A.A.O

Mega Doctor News

- Advertisement -

St. Louis Fred Farias III, O.D., F.A.A.O, Chief Executive Officer of 20/20 Vision Care in McAllen, Texas, has been elected to serve on the American Optometric Association’s (AOA) Board of Trustees. The AOA represents more than 44,000 doctors of optometry and other eye care professionals. Dr. Farias was sworn into office on June 24, 2017, in Washington, DC, during the association’s annual Optometry’s Meeting®.

Over the coming year, Dr. Farias will serve as liaison trustee to the AOA’s Ethics and Values Committee, Multi-Disciplinary Advisory Team, Research and Information Resource Team, Paraoptometric Resource Center Committee, and the Vision Rehabilitation Committee. He’ll also be the Board of Trustees’ representative to affiliate associations in the states of Alaska, California, Hawaii, Nevada, and Oregon.

In 2016, Dr. Farias was named the American Optometric Association’s Optometrist of the Year, and will be this year’s recipient of the Southern College of Optometry (SCO) Lifetime Achievement Award – the highest honor bestowed by the college to one of its alumni. In addition, he is a past president of the Texas Optometric Association, and was its optometrist of the year in 2015. Additionally, he has served as president of the Rio Grande Valley Optometric Society.

- Advertisement -

Dr. Farias has made numerous contributions to state and national optometric organizations, as well as to communities in South Texas, organizing and sponsoring vision screenings for underserved individuals and families.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

DHR Health Raises Over $520K at 20th “Fishing for Hope” Event

DHR Health made a big splash at the 20th Annual “Fishing for Hope” Tournament, held on August 22 at Jim’s Pier in South Padre Island, raising an impressive grand total of $524,130.

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The U.S. Food and Drug Administration approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. 

STHS Behavioral Marks Suicide Prevention Month with Community Chalk Event

Every 11 minutes, someone in the United States dies by suicide, according to the Centers for Disease Control and Prevention (CDC), making it one of the nation's leading causes of death.

Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy

Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.
- Advertisement -